Sunshine Biopharma Inc. has entered an agreement with Lonza for the manufacture of its anti-cancer drug, Adva-27a. Lonza will begin manufacturing at its Nansha, China facility with the remaining key steps to be carried out at its high containment cytotoxic facility in Visp, Switzerland.    “We are delighted to have a global leader like Lonza as our manufacturing partner,” said Dr. Steve N. Slilaty, president and chief executive officer of Sunshine Biopharma. “We have made signi...